License pact for L606, potential long-acting version of Tyvaso, expands
Liquidia has expanded a license agreement with Pharmosa Biopharm, acquiring rights to market L606, a potential inhaled formulation of treprostinil now in a Phase 3 study, across Europe, Japan, and other regions as well as in North America. The two-part and open-label Phase 3 clinical…